Castillo E, Garibay M, Mirabent F

Language: Spanish
References: 10
Page: 580-584
PDF size: 292.01 Kb.

ABSTRACT

Objective: To evaluate the effectiveness of alpha dihidroergocriptine in patients with fibrocystic mastopathy.
Patients and methods: Patients with diagnosis of fibrocystic breast disease were included in a prospective longitudinal blind double, controlled with placebo study. Patients were randomly assigned to one of two treatment groups: of treatment group A: Alpha dihidroergocriptine tablets of 10 mg, group B: Placebo, during 6 months. After to basal evaluation, the patients were revised in a monthly way evaluating the following symptoms and signs: mastalgia, mammary tension, presence of nodules, nipple secretion, and the presence of adverse events.
Results: 39 patients with alpha dihidroergocriptine and 38 with placebo. Mastodinia, a satisfactory response was observed in 100% of alpha dihidroergocriptine group vs 61.11% of placebo group (p = 0.0002). Mastalgia responded in 100% of alpha dihidroergocriptine group vs 64.86% of placebo group (p = 0.0003). Galactorrea responded 100% of alpha dihidroergocriptine group vs 93.33% of the placebo. The nodules in the group alpha dihidroergocriptine disappeared in 23.1% and in 21.1% of the placebo group. Ultrasound evaluation of the nodules did not show significant differences between both groups. Prolactin levels showed a decrease in the group treated with alpha dihidroergocriptine with an important difference between both groups at the end of the 6 months study period. There were not differences in the presence of adverse events between groups.
Conclusions: Alpha dihidroergocriptine is effective in the treatment of fribrocystic breast disease with minimum adverse events when compared with similar drugs.

REFERENCES

1. Stern E. The natural history of macroscopic cyst in the breast. Surg Gynecol Obstet 1972;174:36-40.

2. Winfield A, Page D. The breast. In: Jones III HW, Colston AW, Burnett LS, editors. Novak’s textbook of gynecology. 10th ed. Philadelphia: Lippincott William & Wilkins, 1988;pp:534-56.

3. Zanoio L, Zacche G, Maineti M, et al. Attualita nella terapia della mastopatia fibrocistica. (Update in the therapy of fibrocystic mastopathy). Minerva Ginecol 1987;39(12):833-8.

4. Nazli K, Syed S, Mahmood Mr, et al. Controlled trial of the prolactin inhibitor bromocriptine (Parlodel) in the treatment of severe cyclical mastalgia. Br J Clin Pract 1989;43(9):322-7.

5. Fitzal P, Wolfo G. Comparision of the diagnostic value of the individual examination steps (triple diagnosis) in breast cysts. Ultraschall Med 1990;11(4):202-5.

6. Kubsta E. Diagnosis and therapy of fibrocystic breast disease. Zentralbl Gynacol 1990;112(7):1091-6.

7. Amato C, Cipolia C, Salanito L, et al. Role of ultrasonography in the diagnosis of carcinoma of the breast. G Chir 1990;11:7-8, 435-8.

8. Garci Roig F, Peñar Cortes HT. Imágenes ultrasonográficas de la mastopatía fibroquística tratada con bromocriptina. Ginecol Obstet Mex 1986;54:274-7.

9. Tolino A, Cardone A, Mastrantonio P, et al. Trattamiento della patología mamaria benigna con bromocriptina (Treatment of benign breast pathology with bromocriptine) Riv Ital Ginecol 1977;58(5):371-8.

10. Dogliotti L, Mansel RE. Bromocriptine treatment of cyclical mastalgia/fibrocystic breast disease: update on the European trial. Br J Clin Pract Symp Suppl 1989;68:26-32.